Genetic Blockade of NAAA Cell-specifically Regulates Fatty Acid Ethanolamides (FAEs) Metabolism and Inflammatory Responses

Xiaohua Xie, Yitian Li, Sennan Xu, Pan Zhou, Longhe Yang, Yaping Xu, Yan Qiu, Yungang Yang, Yuhang LiFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates the role of N-acylethanolamine acid amidase (NAAA) in regulating fatty acid ethanolamide (FAE) metabolism and inflammatory responses. By creating NAAA-deficient mice, researchers found that NAAA's function is cell-specific, with its absence in bone marrow-derived cells leading to anti-inflammatory effects, while its absence in other cell types results in tolerance to these effects.

What Problem Does This Paper Address?

Fatty acid ethanolamides (FAEs) are a class of endogenous lipids involved in various physiological processes, including pain and inflammation. While enzymes like FAAH are well-studied for their role in FAE metabolism, the function of N-acylethanolamine acid amidase (NAAA), another key enzyme in this pathway, remains largely unclear. Specifically, how NAAA influences FAE levels and its impact on pain and inflammation in different cell types were unknown. This paper aims to elucidate these roles by genetically manipulating NAAA and observing the consequences.

Methods

The researchers employed several key techniques:

  • CRISPR-Cas9 Gene Editing: This was used to create NAAA-deficient (NAAA<sup>-/-</sup>) mice, effectively knocking out the NAAA gene.
  • Biochemical Assays: Western blotting and immunohistochemistry were used to confirm the absence of NAAA protein in knockout mice and to assess its localization. PEA hydrolytic activity assays were performed to measure the enzyme's function.
  • Lipid Analysis: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was utilized to quantify the levels of various FAEs (PEA, AEA, OEA) in different tissues and cell types.
  • Cell Culture: Primary macrophages were cultured to study NAAA's role in these specific immune cells.
  • Animal Models of Inflammation and Pain:
    • Lipopolysaccharide (LPS)-induced Acute Lung Injury (ALI): To assess anti-inflammatory effects.
  • Carrageenan-induced Hyperalgesia: To evaluate analgesic effects in an inflammatory pain model.
  • Sciatic Nerve Injury (SNI)-induced Neuropathic Pain: To assess analgesic effects in a nerve injury pain model.
  • Bone Marrow (BM) Transplantation: This crucial technique involved creating chimeric mice by transferring BM cells between WT and NAAA<sup>-/-</sup> mice. This allowed researchers to dissect the cell-specific roles of NAAA in different tissues and organs.

Datasets

Not discussed in the paper. The study relies on experimental data generated from animal models and biochemical assays.

Key Insights and Ideas

  • Cell-Specific NAAA Function: The most striking finding is that NAAA's role in FAE metabolism and its impact on inflammation and pain are highly cell-specific. This challenges the notion of a uniform effect across all tissues.
  • Bone Marrow as a Key Site: NAAA in bone marrow (BM) and BM-derived cells (like macrophages) appears critical for regulating PEA and AEA levels, and for mediating anti-inflammatory responses.
  • Tolerance to NAAA Blockade: While acute inhibition of NAAA (using the drug F96) shows potent anti-inflammatory and analgesic effects, genetic knockout of NAAA leads to a tolerance to these effects, particularly in non-BM cells. This suggests compensatory mechanisms are at play.
  • NAAA's Limited Role in General PEA Metabolism: Contrary to previous assumptions, NAAA's genetic deletion had minimal impact on PEA levels in most tissues under physiological conditions, suggesting FAAH might be the primary enzyme for PEA degradation in these contexts. However, NAAA's role in immune cells for PEA metabolism was confirmed.
  • Potential for Therapeutic Intervention: Despite the tolerance observed in knockout mice, the study still highlights NAAA as a potential therapeutic target, especially in specific pathological conditions where its role might be amplified.

Key Results

  • FAE Levels: NAAA deficiency increased PEA and AEA levels in bone marrow and macrophages, and AEA levels in the lungs.
  • Anti-inflammatory Effects: NAAA<sup>-/-</sup> mice showed moderately effective anti-inflammatory effects in LPS-induced ALI, but these were less pronounced than those seen with acute NAAA inhibition by F96.
  • Analgesic Effects: NAAA<sup>-/-</sup> mice exhibited poor analgesic effects in carrageenan-induced hyperalgesia and SNI-induced neuropathic pain models, contrasting with the strong analgesia observed with F96 treatment.
  • BM Chimera Experiments:
    • Transferring WT BM into NAAA<sup>-/-</sup> recipients (or NAAA<sup>-/-</sup> BM into WT recipients) revealed that NAAA in BM-derived cells is crucial for potent analgesic and anti-inflammatory phenotypes.
  • Conversely, when NAAA was absent in non-BM cells but present in BM cells, it led to analgesic and anti-inflammatory tolerance.

Limitations and Future Work

  • Discrepancy with Previous Studies: The authors acknowledge a discrepancy with a previous study (Fotio et al.) that reported NAAA deletion blocked CCI-induced hypersensitivity. They hypothesize this could be due to differences in the gene editing methods used (CRISPR-Cas9 vs. loxP-Cre).
  • Mechanism of Tolerance: The precise mechanisms underlying the observed analgesic and anti-inflammatory tolerance in NAAA<sup>-/-</sup> mice are not fully elucidated. The authors suggest compensatory mechanisms in non-BM cells or receptor desensitization as possibilities, but note that repeated F96 treatment did not induce tolerance, and receptor agonist studies were inconclusive.
  • Role of NAAA in Non-BM Cells: The study points to a need for further investigation into the specific role of NAAA in non-BM cells, as its absence there seems to contribute to tolerance.
  • Specificity of F96: While F96 is highly selective for NAAA, the authors cannot entirely exclude the possibility of off-target effects contributing to its potent effects compared to genetic knockout. Further studies are needed to confirm F96's specificity.

Summary updated

Abstract

N-Acylethanolamine acid amidase (NAAA) is a lysosomal enzyme responsible for the hydrolysis of fatty acid ethanolamides (FAEs). However, the role of NAAA in FAEs metabolism and regulation of pain and inflammation remains mostly unknown. Here, we generated NAAA-deficient (NAAA<sup>-/-</sup>) mice using CRISPR-Cas9 technique, and found that deletion of NAAA increased PEA and AEA levels in bone marrow (BM) and macrophages, and elevated AEA levels in lungs. Unexpectedly, genetic blockade of NAAA caused moderately effective anti-inflammatory effects in lipopolysaccharides (LPS)-induced acute lung injury (ALI), and poor analgesic effects in carrageenan-induced hyperalgesia and sciatic nerve injury (SNI)-induced mechanical allodynia. These data contrasted with acute (single dose) or chronic NAAA inhibition by F96, which produced marked anti-inflammation and analgesia in these models. BM chimera experiments indicated that these phenotypes were associated with the absence of NAAA in non-BM cells, whereas deletion of NAAA in BM or BM-derived cells in rodent models resulted in potent analgesic and anti-inflammatory phenotypes. When combined, current study suggested that genetic blockade of NAAA regulated FAEs metabolism and inflammatory responses in a cell-specifical manner.
BibTeX
@inproceedings{xie2022genetic,
  author = {Xiaohua Xie and Yitian Li and Sennan Xu and Pan Zhou and Longhe Yang and Yaping Xu and Yan Qiu and Yungang Yang and Yuhang Li and Yuhang Li and Yuhang Li},
  title = {{Genetic Blockade of NAAA Cell-specifically Regulates Fatty Acid Ethanolamides (FAEs) Metabolism and Inflammatory Responses}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2021.817603},
}
Figure